AstraZeneca to unveil pivotal Phase III oncology data at ESMO 2026
AstraZeneca will present more than 100 abstracts at the European Society for Medical Oncology Congress, including data from five Phase III trials, four of which will be featured in Presidential Symposia. The highlighted trials are CLARITY‑Gastric01 (Sone‑Ve in CLDN18.2‑positive gastric cancer), SAFFRON (Tagrisso + savolitinib in MET‑driven EGFR‑mutated lung cancer), VOLGA (Imfinzi + enfortumab vedotin in muscle‑invasive bladder cancer) and DeLLphi‑305 (Imfinzi + tarlatamab in extensive‑stage small‑cell lung cancer). Executives said the data aim to set new standards of care and improve overall survival for patients.
Why it matters
The upcoming overall‑survival data could reshape market expectations for AstraZeneca’s oncology portfolio and influence future sales forecasts. Investors should monitor the results, as positive outcomes may act as a catalyst for the stock.
Key facts
- 1More than 100 abstracts will be presented at ESMO 2026, including data from five Phase III trials. marketscreener.com
- 2Four of the Phase III trials will be featured in Presidential Symposia. marketscreener.com
- 3CLARITY‑Gastric01 evaluates Sone‑Ve in second‑line or later CLDN18.2‑positive (≥25%) advanced gastric or gastro‑oesophageal junction cancers. marketscreener.com
- 4Approximately 60% of patients in CLARITY‑Gastric01 have CLDN18.2 expression ≥25%. marketscreener.com
- 5SAFFRON tests Tagrisso + savolitinib in MET‑driven EGFR‑mutated non‑small‑cell lung cancer after prior treatment versus platinum‑based chemotherapy. marketscreener.com
- 6VOLGA studies perioperative Imfinzi combined with enfortumab vedotin in muscle‑invasive bladder cancer patients ineligible for cisplatin‑based chemotherapy versus surgery with or without adjuvant therapy. marketscreener.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.